Economic Evaluation of Transitioning to the 20-Valent Pneumococcal Conjugate Vaccine in the Dutch Paediatric National Immunisation Programme. [PDF]
Çakar E +6 more
europepmc +1 more source
Correction to: Immunogenicity and Safety of the Higher-Valent Pneumococcal Conjugate Vaccine vs the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials. [PDF]
europepmc +1 more source
Correction to: Radiographically confirmed pneumonia in Malawian children and associated Pneumococcal carriage after introduction of the 13-valent Pneumococcal conjugate vaccine. [PDF]
Mzumara G +13 more
europepmc +1 more source
Long-term impact of 10-valent pneumococcal conjugate vaccine among children <5 years, Uganda, 2014-2021. [PDF]
Wanyana MW +7 more
europepmc +1 more source
Cost-effectiveness analysis of the 13-valent pneumococcal conjugate vaccine administered to children under 5 years of age in the Republic of Moldova. [PDF]
Balanuta AM +4 more
europepmc +1 more source
Delayed Transition to 20-Valent Pneumococcal Conjugate Vaccine in Pediatric National Immunization Programs: Forgone Public Health and Economic Benefit. [PDF]
Perdrizet J +6 more
europepmc +1 more source
Immunogenicity of yellow fever vaccine co-administered with 13-valent pneumococcal conjugate vaccine in rural Gambia: A cluster-randomised trial. [PDF]
Osei I +12 more
europepmc +1 more source
The Safety and Immunogenicity of a 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) in Infants: A Double-Blind, Randomized, Phase III Trial [PDF]
Zhiqiang Xie +13 more
openalex +1 more source

